{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+cap", "query": { "intervention": "Standard cap" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 597, "total_pages": 60, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+cap&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-06T20:53:20.695Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06106308", "title": "Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer", "CRC", "KRAS/NRAS Mutation" ], "interventions": [ { "name": "Onvansertib", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cardiff Oncology", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 110, "start_date": "2024-02-27", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2026-06-16", "last_synced_at": "2026-09-06T20:53:20.695Z", "location_count": 41, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 35 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06106308" }, { "nct_id": "NCT03615326", "title": "Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastric Neoplasms", "Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "S-1", "type": "DRUG" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 738, "start_date": "2018-10-05", "completion_date": "2025-11-12", "has_results": true, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-09-06T20:53:20.695Z", "location_count": 23, "location_summary": "Los Angeles, California • Monterey, California • Orange, California + 19 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Monterey", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Newnan", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03615326" }, { "nct_id": "NCT03151408", "title": "An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Pracinostat", "type": "DRUG" }, { "name": "Placebos", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Helsinn Healthcare SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 406, "start_date": "2017-06-23", "completion_date": "2020-08-20", "has_results": true, "last_update_posted_date": "2022-03-10", "last_synced_at": "2026-09-06T20:53:20.695Z", "location_count": 30, "location_summary": "Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 25 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03151408" }, { "nct_id": "NCT01268280", "title": "Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myasthenia Gravis" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "250 mg CK-2017357", "type": "DRUG" }, { "name": "500 mg CK-2017357", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cytokinetics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 32, "start_date": "2010-12", "completion_date": "2012-10", "has_results": false, "last_update_posted_date": "2019-09-24", "last_synced_at": "2026-09-06T20:53:20.695Z", "location_count": 15, "location_summary": "Fresno, California • Orange, California • San Francisco, California + 12 more", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "New Britain", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01268280" }, { "nct_id": "NCT02184585", "title": "Comparative Bioavailability of Two Fixed Dose Combination (FDC) Formulations of Dutasteride and Tamsulosin Hydrochloride Relative to Co-administration of Dutasteride With Tamsulosin Hydrochloride in Healthy Male Subjects Under Fed and Fasted States", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostatic Hyperplasia" ], "interventions": [ { "name": "Treatment sequence A", "type": "DRUG" }, { "name": "Treatment sequence B", "type": "DRUG" }, { "name": "Treatment sequence C", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "MALE", "summary": "18 Years to 65 Years · Male only" }, "enrollment_count": 84, "start_date": "2014-07-10", "completion_date": "2015-02-23", "has_results": false, "last_update_posted_date": "2018-06-19", "last_synced_at": "2026-09-06T20:53:20.695Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02184585" }, { "nct_id": "NCT01248715", "title": "Rapid Empiric Treatment With Oseltamivir Study (RETOS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Influenza", "Pneumonia" ], "interventions": [ { "name": "oseltamivir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Louisville", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1107, "start_date": "2010-11", "completion_date": "2016-05", "has_results": true, "last_update_posted_date": "2023-06-15", "last_synced_at": "2026-09-06T20:53:20.695Z", "location_count": 5, "location_summary": "Louisville, Kentucky", "locations": [ { "city": "Louisville", "state": "Kentucky" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT01248715" }, { "nct_id": "NCT05592613", "title": "Next Generation Ingestible Sensors for Medication Adherence Measurement", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infection", "Adherence, Medication", "Adherence, Treatment", "Pre-Exposure Prophylaxis", "Antiretroviral Therapy" ], "interventions": [ { "name": "Next-generation Reader and ID-Cap System", "type": "DEVICE" }, { "name": "Truvada for pre-exposure prophylaxis (PrEP)", "type": "DRUG" }, { "name": "Biktarvy for antiretroviral therapy (ART)", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2023-02-06", "completion_date": "2024-07-25", "has_results": false, "last_update_posted_date": "2024-09-25", "last_synced_at": "2026-09-06T20:53:20.695Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05592613" }, { "nct_id": "NCT00809835", "title": "Galantamine to Enhance Cognitive Behavioral Therapy for Cocaine Abuse", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cocaine Dependence" ], "interventions": [ { "name": "Galantamine", "type": "DRUG" }, { "name": "Computer Assisted Cognitive Behavioral Therapy (CBT)", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 120, "start_date": "2007-12", "completion_date": "2015-01", "has_results": true, "last_update_posted_date": "2019-01-30", "last_synced_at": "2026-09-06T20:53:20.695Z", "location_count": 2, "location_summary": "Bridgeport, Connecticut • Stratford, Connecticut", "locations": [ { "city": "Bridgeport", "state": "Connecticut" }, { "city": "Stratford", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00809835" }, { "nct_id": "NCT07032389", "title": "A Polypill for Acute Coronary Syndrome", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Coronary Syndrome" ], "interventions": [ { "name": "Polypill", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1000, "start_date": "2025-12-05", "completion_date": "2030-07-31", "has_results": false, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-09-06T20:53:20.695Z", "location_count": 2, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07032389" }, { "nct_id": "NCT02330653", "title": "Fecal Microbiota Transplant (FMT) in Pediatric Active Ulcerative Colitis and Pediatric Active Crohn's Colitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Inflammatory Bowel Diseases", "Ulcerative Colitis", "Crohn Disease" ], "interventions": [ { "name": "Fecal Microbiota Transplant (FMT)", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Stacy A. Kahn", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "5 Years to 30 Years" }, "enrollment_count": 15, "start_date": "2015-11", "completion_date": "2019-04-08", "has_results": true, "last_update_posted_date": "2023-10-16", "last_synced_at": "2026-09-06T20:53:20.695Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02330653" } ] }